Literature DB >> 15098856

Pyridoxine hydrochloride treatment of carpal tunnel syndrome: a review.

Elaine Aufiero1, Todd P Stitik, Patrick M Foye, Boqing Chen.   

Abstract

It has been hypothesized that idiopathic carpal tunnel syndrome (CTS) is a manifestation of vitamin B6 deficiency. Some claim that B6 supplementation can alleviate symptoms. Others argue that pain relief occurs because of vitamin B6's anti-nociceptive properties or because B6 supplementation addresses an unrecognized peripheral neuropathy. Few studies on CTS and B6 employed electrodiagnostic techniques in diagnosis, and few showed a correlation between symptoms and improved electrodiagnostic parameters with supplementation. Other studies failed to measure or estimate B6 levels. Nevertheless, it appears reasonable to recommend vitamin B6 supplementation to people with CTS. Some patients will improve symptomatically with low risks of toxicity in recommended doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098856     DOI: 10.1111/j.1753-4887.2004.tb00030.x

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  4 in total

Review 1.  Carpal tunnel syndrome: "no-stitch endoscopic surgery" as a treatment option.

Authors:  Scott R Gibbs; Kyle O Colle; Christine M Byrd
Journal:  Mo Med       Date:  2010 Mar-Apr

2.  Effect of vitamin b6 on clinical symptoms and electrodiagnostic results of patients with carpal tunnel syndrome.

Authors:  Mahnaz Talebi; Sasan Andalib; Shohreh Bakhti; Hormoz Ayromlou; Alireza Aghili; Ashraf Talebi
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 3.  Carpal tunnel syndrome and vitamin B6.

Authors:  Milly Ryan-Harshman; Walid Aldoori
Journal:  Can Fam Physician       Date:  2007-07       Impact factor: 3.275

4.  Effect of vitamin B6 on pain, disease severity, and psychological profile of fibromyalgia patients; a randomized, double-blinded clinical trial.

Authors:  Banafsheh Ghavidel-Parsa; Arvin Naeimi; Faeze Gharibpoor; Nazila Sattari; Atefeh Jafari; Irandokht Shenavar Masooleh; Ali Montazeri
Journal:  BMC Musculoskelet Disord       Date:  2022-07-13       Impact factor: 2.562

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.